1584 – Radionuclide Imaging for for the diagnosis of transthyretin amyloid cardiomyopathy

Page last updated: 21 November 2019

Application Detail

Description of Medical Service

Radionuclide scintigraphy with 99mTc-labeled pyrophosphate (PYP), 99mTC-labeled oxidronate (HDP) or 99mTc-labeled 3,3-diphosphono-1,2-propanodicarboxylic acid (DPD) is sensitive and specific for imaging cardiac ATTR amyloid and enables a diagnosis of ATTR-CM. A standard protocol includes whole-body scans after injection. Heart and whole-body retention and heart to whole-body retention ratio can be semi-quantitatively analysed from early whole-body counts.

Description of Medical Condition

Transthyretin amyloid cardiomyopathy (ATTR-CM) is a life-threatening disease characterised by accumulation of amyloid fibrils composed of misfolded transthyretin protein in the heart. Misfolded monomers or oligomers of transthyretin are deposited in the myocardium, leading to cardiomyopathy and symptoms of heart failure.

ATTR-CM is a late-onset disease occurring predominately in male patients aged 60 years or older. ATTR-CM can be inherited as an autosomal dominant trait caused by pathogenic mutations in the transthyretin gene TTR (ATTRm) or by deposition of wild-type transthyretin protein (ATTRwt), previously called senile systemic amyloidosis.

Reason for Application

New MBS item

Medical Service Type


Previous Application Number/s

Not applicable

Associated Documentation

Application Form

Application Form (PDF 1915 KB)
Application Form (Word 622 KB)

Consultation Survey

Consultation Survey (PDF 488 KB)
Consultation Survey (Word 70 KB)

PICO Confirmation


Assessment Report


Public Summary Document

Public Summary Document (PDF 454 KB)
Public Summary Document (Word 66 KB)

Meetings for this Application






1-2 August 2019